Direct-to-Consumer Raw Data and a Request for Clinical Action
A 29-year-old woman brings raw data from a direct-to-consumer (DTC) genotyping service. A third-party interpretation tool flags a variant in a cancer predisposition gene and reports it as 'pathogenic.' She has no personal or family history of cancer. She asks her primary care provider to order a mastectomy referral and to test her 5-year-old daughter. She is extremely distressed and has already posted the result online. The variant is a well-known pathogenic founder variant in some populations, but the DTC array genotyping has known false-positive rates for this variant.
1. How do you respond to her request for surgery and for testing her daughter?
Read the worked answer
Reasoning:
Do not act on DTC raw data alone. Array-based genotyping has limited accuracy; the result must be confirmed in a CLIA-certified (or equivalent) clinical laboratory before any clinical action. Explain this clearly and kindly.
Offer clinical confirmation testing. If confirmed pathogenic, then discuss risk and management with a high-risk clinic. If not confirmed, explain the false-positive possibility and the distress that can follow.
Surgery request: Decline to refer for prophylactic mastectomy based on unconfirmed DTC data. Management should follow confirmed results and established guidelines.
Daughter testing: Predictive testing of a 5-year-old for an adult-onset condition is not appropriate when there is no childhood benefit. Explain this and the rationale (preserving the child's future autonomy).
Psychosocial support: Acknowledge distress, address the public posting (privacy implications), and offer genetic counselling.
Education: Explain the difference between DTC genotyping, DTC sequencing, and clinical testing.
2. What ethical and professional issues arise from the online posting and the third-party interpretation?
Read the worked answer
Issues:
- Privacy: Public posting of genetic information can affect insurance and family members. Discuss the implications and the limits of control over posted data.
- Accuracy and duty of care: Third-party tools vary in quality and may misinterpret variants. The clinician's duty is to verify before acting.
- Non-maleficence: Acting on unconfirmed data risks harm from unnecessary surgery.
- Autonomy and informed choice: She has a right to information, but she also needs accurate information to make choices.
- Family implications: A confirmed pathogenic variant would have implications for relatives; discuss cascade testing only after confirmation.
- Professional boundaries: The clinician should not simply dismiss the DTC result; dismissing it can erode trust. Explain the reasoning and offer a clear path forward.
- Documentation: Record the discussion, the confirmation plan, and the rationale for declining immediate referral.